BioSpace News Archive

Global Industry Leaders Join Inkbit to Enable High-Volume Production of Precision Multi-Material Parts

Biodesix, Inc. the leader in lung cancer diagnostics, today announced that Tri-Star Health in Nashville, TN, the region’s largest, most comprehensive healthcare provider, is the first hospital system in the U.S. to adopt the recently launched Nodify XL2™ proteomic nodule classifier for incidental lung nodule management. 1.6 million lung nodules are detected incidentally each year in the U.S., but fewer than five percent turn out to be malignan

Teladoc Health, Inc., the global leader in virtual care, announced today that Jason Gorevic, chief executive officer, and Mala Murthy, chief financial officer, will participate in the following upcoming investor events

Beyond Air, Inc. announced it would be attending the 2019 American Association for Respiratory Care being held on November 9-12, 2019 in New Orleans.

Krystal Biotech Inc., a gene therapy company developing medicines to treat dermatological diseases, announced financial results for third quarter 2019, recent corporate highlights and upcoming milestones.

Reminds Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, will announce financial results for the third quarter ended September 30, 2019 on Tuesday, November 12, 2019, after the NASDAQ market close.

Fresenius Medical Care North America’s Renal Therapies Group, the leading provider of kidney care products, today announced the launch of AquaBplus and AquaC UNO H water purification systems that will be available to all dialysis centers and hospitals in North America in the first quarter of 2020.

Participation in event sets stage for ongoing partnerships and engagement with researchers and drug developers based in China

PsychoGenics Inc., announced the appointment of Mark A. Varney, Ph.D., as Chief Scientific Officer (CSO). This appointment reflects the Company’s growth in Central Nervous System (CNS) drug discovery and clinical development, and its continued commitment to the development of proprietary technologies to support internal and partnered drug discovery and translational research.